Erasca wins FDA Fast Track for ERAS-0015 in pancreatic cancer
Erasca says the FDA granted Fast Track designation to its Pan-RAS molecular glue ERAS-0015 for patients with metastatic pancreatic adenocarcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.